The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease

blonca9
Jan 29, 2024
1 min read

Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing, how Stargardt as an indication is a natural fit as a proof of concept, and why he believes FDA clearance of the IND without ex-U.S. clinical data is meaningful.

Recent Posts

See All

Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry

The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight